Schizophrenia and Psychosis

A new study to be published in the next issue of Schizophrenia Research examines patients suffering from a first-episode of psychosis who stop taking any antipsychotic drugs. The researchers attempt to identify variables that can serve as predictors of the successful discontinuation of antipsychotics. They find, for example, that those who discontinue the drugs have, on average, the same outcomes as those who stay on them, and that those who have better social integration are more likely to discontinue without relapse.

Columnist Nev Jones writes about the lack of adequate care for people in the US experiencing a first-episode of psychosis. “Evidence-based (or informed) psychotherapies...

For Philly.com, staff writer Stacey Burling reports on the PolicyLab analysis of psychiatric drug use among Pennsylvania children on Medicaid.  “Many children in foster...

There is a substantial body of evidence suggesting that not getting enough omega-3 fatty acids in your diet may be connected to a diverse array of psychiatric symptoms. In a new study published this month, psychiatrist Robert McNamara and Erik Messamore provide an overview of the evidence and call for screening of omega-3 deficiency in people experiencing symptoms associated with ADHD, depression, mood disorders, and psychosis.

A pathbreaking new study out of Finland suggests that early intervention programs for youth experiencing psychotic-like symptoms may see the greatest improvement when treatment works within the home rather than in a hospital setting. The research, to be published in next month’s issue of Psychiatry Research, found greater improvement in functioning, depression, and hopelessness among teens in a new need-adapted Family and Community oriented Integrative Treatment Model (FCTM) program.

A study published in this month’s issue of the Social Psychiatry and Psychiatric Epidemiology found that perceived discrimination related to minority status may precede...

"It's no secret that stimulant medications such as Adderall that are prescribed to treat symptoms of ADHD are sometimes used as 'study drugs' aimed...

Benedict Carey of the New York Times reports on the success of new schizophrenia and psychosis programs that provide family counseling and job and...

"Eleanor Longden started hearing voices when she was 18. She was drugged and hospitalised, then told she was schizophrenic. A psychiatrist even told her...

MIA contributor Jonathan Leo, writing for Slate, weighs in on the research that claims to have discovered a genetic basis for schizophrenia. “We now...

Last week, the headlines blared: "Schizophrenia breakthrough as genetic study reveals link to brain changes!"  We heard that our best hope for treating “schizophrenia” is to understand it at a genetic level, and that this new breakthrough would get us really started on that mission, as it showed how a genetic variation could lead to the more intense pruning of brain connections, which is often seen in those diagnosed with schizophrenia.  “For the first time, the origin of schizophrenia is no longer a complete black box,” said one (while admitting that "it's still early days").  The acting director of the National Institute of Mental Health (NIMH) described the study as “a crucial turning point in the fight against mental illness.” But is all this hype justified?

In a study published yesterday, researchers from the Nippon Medical School in Tokyo bring attention to a condition known as neuroleptic-induced deficit syndrome (NIDS)...

Dutch psychiatrist and epidemiologist, Jim van Os, has renewed his call to drop schizophrenia as a disease classification. “Several recent papers by different authors...

“Overall, this study showed that the information and awareness campaign had almost no significant effects on the general public's attitudes toward people affected by either schizophrenia or depression,” the researchers, led by German medical sociologist Anna Makowski, wrote. “One could assume that deeply rooted convictions cannot be modified by rather time-limited and general activities targeted at the public.”

In recent months, two teams of researchers in the UK and the US published complementary findings about the epigenetic origins of schizophrenia that have scientific communities who indulge in ‘genetic conspiracy theories’ abuzz. While these results are intriguing, and no doubt involve pathbreaking research methodologies, this line of thought represents a decontextualized understanding both of the symptoms that are typically associated with schizophrenia, and their causes.

A study out of the University of Buffalo explores the use of Narrative Exposure Therapy to treat youth PTSD and substance abuse. “Trauma is...

In this month’s issue of Psychological Medicine, researchers from King’s College London found evidence for associations between different types of childhood adversity and specific symptoms associated with psychosis. As current categorical approaches to psychosis and schizophrenia diagnoses come under increasing scrutiny, this study adds support to sociological and psychological theories and treatments.

The Boston Globe reports on the discovery of a newly recognized neurological disease, anti-NMDA receptor encephalitis. The disease is believed to be caused when the body’s immune system attacks proteins in the brain associated with the communication of neurons.

PsychCentral covers new research linking social deprivation, population density and inequality with higher rates of psychotic symptoms and diagnoses for schizophrenia. “This is important because other research has shown that many health and social outcomes also tend to be optimal when societies are more equal.”

Revealing the false information provided about psychiatry should cause any thinking person, patient, thought-leader or politician to wonder: “how many otherwise normal or potentially curable people over the last half century of psych drug propaganda have actually been mis-labeled as mentally ill (and then mis-treated) and sent down the convoluted path of therapeutic misadventures – heading toward oblivion?”

In a featured article for Psychiatric Services, psychiatrists from Dartmouth raise the alarm on the increasing numbers of children prescribed dangerous antipsychotic drugs. Despite the fact that data on the safety of long-term use of these drugs in this vulnerable population “do not exist,” the rate of children and adolescents being prescribed antipsychotic drugs have continued to increase over the past fifteen years.

The official voice of the American Psychiatric Association covers the short and long term side-effects of antipsychotics and promotes the use of therapeutic alternatives...

On Monday, the US Supreme Court declined to hear Johnson and Johnson’s final appeal, forcing the company to pay $124 million for the deceptive marketing of the antipsychotic Risperdal. In 2011, South Carolina ordered the company to pay $327 million for pursuing “profits-at-all-costs” in its efforts to persuade doctors to prescribe their drug, but the fine was lowered to $136 million last year. The company had hoped to argue that the remaining penalties constituted an “excessive fine” and was supported by PhRMA, the Washington Legal Foundation, the Cato Institute and the Chamber of Commerce.

“A little background digging revealed to me that this study is the tip of a new iceberg relative to ADHD diagnosis, stimulant treatment, and...

“Do they make people less aggressive? Yes, sometimes they do. Will they sedate people? Absolutely. Will they make kids easier to manage? They will,” Robert Whitaker tells Liz Spikol for Philadelphia Magazine. “But I know of no study that shows that medicating these kids long-term will help them grow up and thrive. The developing brain is a very delicate thing. The narrative is that these side effects are mild, and that’s just not true, and that the benefits are well-established, and so often they’re not.”